|
1
|
Estey EH: Acute myeloid leukemia: 2013
update on risk-stratification and management. Am J Hematol.
88:318–327. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shipley JL and Butera JN: Acute
myelogenous leukemia. Hematol. 37:649–658. 2009.
|
|
3
|
Shaffer BC, Gillet JP, Patel C, Baer MR,
Bates SE and Gottesman MM: Drug resistance: Still a daunting
challenge to the successful treatment of AML. Drug Resist Updat.
15:62–69. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Andreeff M and Konopleva M: Mechanisms of
drug resistance in AML. Cancer Treat Res. 112:237–262. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Holleman A, Cheok MH, den Boer ML, Yang W,
Veerman AJ, Kazemier KM, Pei D, Cheng C, Pui CH, Relling MV, et al:
Gene-expression patterns in drug-resistant acute lymphoblastic
leukemia cells and response to treatment. N Engl J Med.
351:533–542. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Beesley AH, Firth MJ, Ford J, Weller RE,
Freitas JR, Perera KU and Kees UR: Glucocorticoid resistance in
T-lineage acute lymphoblastic leukaemia is associated with a
proliferative metabolism. Br J Cancer. 100:1926–1936. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhao F, Mancuso A, Bui TV, Tong X, Gruber
JJ, Swider CR, Sanchez PV, Lum JJ, Sayed N, Melo JV, et al:
Imatinib resistance associated with BCR-ABL upregulation is
dependent on HIF-1alpha-induced metabolic reprograming. Oncogene.
29:2962–2972. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kluza J, Jendoubi M, Ballot C, Dammak A,
Jonneaux A, Idziorek T, Joha S, Dauphin V, Malet-Martino M,
Balayssac S, et al: Exploiting mitochondrial dysfunction for
effective elimination of imatinib-resistant leukemic cells. PLoS
One. 6:e219242011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kominsky DJ, Klawitter J, Brown JL, Boros
LG, Melo JV, Eckhardt SG and Serkova NJ: Abnormalities in glucose
uptake and metabolism in imatinib-resistant human BCR-ABL-positive
cells. Clin Cancer Res. 15:3442–3450. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Klawitter J, Kominsky DJ, Brown JL,
Klawitter J, Christians U, Leibfritz D, Melo JV, Eckhardt SG and
Serkova NJ: Metabolic characteristics of imatinib resistance in
chronic myeloid leukaemia cells. Br J Pharmacol. 158:588–600. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Herst PM, Howman RA, Neeson PJ, Berridge
MV and Ritchie DS: The level of glycolytic metabolism in acute
myeloid leukemia blasts at diagnosis is prognostic for clinical
outcome. J Leukoc Biol. 89:51–55. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hulleman E, Kazemier KM, Holleman A,
VanderWeele DJ, Rudin CM, Broekhuis MJ, Evans WE, Pieters R and Den
Boer ML: Inhibition of glycolysis modulates prednisolone resistance
in acute lymphoblastic leukemia cells. Blood. 113:2014–2021. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Akers LJ, Fang W, Levy AG, Franklin AR,
Huang P and Zweidler-McKay PA: Targeting glycolysis in leukemia: A
novel inhibitor 3-BrOP in combination with rapamycin. Leuk Res.
35:814–820. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pradelli LA, Bénéteau M, Chauvin C,
Jacquin MA, Marchetti S, Muñoz-Pinedo C, Auberger P, Pende M and
Ricci JE: Glycolysis inhibition sensitizes tumor cells to death
receptors-induced apoptosis by AMP kinase activation leading to
Mcl-1 block in translation. Oncogene. 29:1641–1652. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Moreno-Sánchez R, Rodríguez-Enríquez S,
Saavedra E, Marín-Hernández A and Gallardo-Pérez JC: The
bioenergetics of cancer: Is glycolysis the main ATP supplier in all
tumor cells? Biofactors. 35:209–225. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen JQ and Russo J: Dysregulation of
glucose transport, glycolysis, TCA cycle and glutaminolysis by
oncogenes and tumor suppressors in cancer cells. Biochim Biophys
Acta. 1826:370–384. 2012.PubMed/NCBI
|
|
17
|
Gillies RJ, Robey I and Gatenby RA: Causes
and consequences of increased glucose metabolism of cancers. J Nucl
Med. 49(Suppl 2): S24–S42. 2008. View Article : Google Scholar
|
|
18
|
Xu RH, Pelicano H, Zhou Y, Carew JS, Feng
L, Bhalla KN, Keating MJ and Huang P: Inhibition of glycolysis in
cancer cells: A novel strategy to overcome drug resistance
associated with mitochondrial respiratory defect and hypoxia.
Cancer Res. 65:613–621. 2005.PubMed/NCBI
|
|
19
|
World Medical Association: World Medical
Association Declaration of Helsinki: Ethical principles for medical
research involving human subjects. JAMA. 310:2191–2194. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen CY, Jia JH, Zhang MX, Meng YS, Kong
DX, Pan XL and Yu XP: Proteomic analysis on multi-drug resistant
cells HL-60/DOX of acute myeloblastic leukemia. Chin J Physiol.
48:115–120. 2005.PubMed/NCBI
|
|
21
|
Wang D, Wang Z, Tian B, Li X, Li S and
Tian Y: Two hour exposure to sodium butyrate sensitizes bladder
cancer to anticancer drugs. Int J Urol. 15:435–441. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chinese Chemotherapy Symposium of
Leukemia: The chemotherapy response criteria of acute leukemia
Chin. J Hematol. 9:183–184. 1988.
|
|
23
|
Reagan JL, Fast LD, Safran H, Nevola M,
Winer ES, Castillo JJ, Butera JN, Quesenberry MI, Young CT and
Quesenberry PJ: Cellular immunotherapy for refractory hematological
malignancies. J Transl Med. 11:1502013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
de Figueiredo-Pontes LL, Pintão MC,
Oliveira LC, Dalmazzo LF, Jácomo RH, Garcia AB, Falcão RP and Rego
EM: Determination of P-glycoprotein, MDR-related protein 1, breast
cancer resistance protein, and lung-resistance protein expression
in leukemic stem cells of acute myeloid leukemia. Cytometry B Clin
Cytom. 74:163–168. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kaufmann SH, Karp JE, Jones RJ, Miller CB,
Schneider E, Zwelling LA, Cowan K, Wendel K and Burke PJ:
Topoisomerase II levels and drug sensitivity in adult acute
myelogenous leukemia. Blood. 83:517–530. 1994.PubMed/NCBI
|
|
26
|
Suh DH, Kim MK, No JH, Chung HH and Song
YS: Metabolic approaches to overcoming chemoresistance in ovarian
cancer. Ann N Y Acad Sci. 1229:53–60. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhou Y, Tozzi F, Chen J, Fan F, Xia L,
Wang J, Gao G, Zhang A, Xia X, Brasher H, et al: Intracellular ATP
levels are a pivotal determinant of chemoresistance in colon cancer
cells. Cancer Res. 72:304–314. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gatenby RA and Gillies RJ: Why do cancers
have high aerobic glycolysis? Nat Rev Cancer. 4:891–899. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Herst PM, Hesketh EL, Ritchie DS and
Berridge MV: Glycolytic metabolism confers resistance to combined
all-trans retinoic acid and arsenic trioxide-induced apoptosis in
HL60rho0 cells. Leuk Res. 32:327–333. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhao Y, Butler EB and Tan M: Targeting
cellular metabolism to improve cancer therapeutics. Cell Death Dis.
4:e5322013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pedersen PL, Mathupala S, Rempel A,
Geschwind JF and Ko YH: Mitochondrial bound type II hexokinase: A
key player in the growth and survival of many cancers and an ideal
prospect for therapeutic intervention. Biochim Biophys Acta.
1555:14–20. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ulanovskaya OA, Cui J, Kron SJ and Kozmin
SA: A pairwise chemical genetic screen identifies new inhibitors of
glucose transport. Chem Biol. 18:222–230. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wolf A, Agnihotri S, Micallef J, Mukherjee
J, Sabha N, Cairns R, Hawkins C and Guha A: Hexokinase 2 is a key
mediator of aerobic glycolysis and promotes tumor growth in human
glioblastoma multiforme. J Exp Med. 208:313–326. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Teng CL, Young JH, Hsu SL, Chou G, Kuo IT,
Yu CY and Hwang GY: Lactate dehydrogenase, not vascular endothelial
growth factor or basic fibroblast growth factor, positively
correlates to bone marrow vascularity in acute myeloid leukemia. J
Chin Med Assoc. 69:534–537. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shannon AM, Bouchier-Hayes DJ, Condron CM
and Toomey D: Tumour hypoxia, chemotherapeutic resistance and
hypoxia-related therapies. Cancer Treat Rev. 29:297–307. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
López-Ríos F, Sánchez-Aragó M,
García-García E, Ortega AD, Berrendero JR, Pozo-Rodríguez F,
López-Encuentra A, Ballestín C and Cuezva JM: Loss of the
mitochondrial bioenergetic capacity underlies the glucose avidity
of carcinomas. Cancer Res. 67:9013–9017. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sánchez-Aragó M and Cuezva JM: The
bioenergetic signature of isogenic colon cancer cells predicts the
cell death response to treatment with 3-bromopyruvate, iodoacetate
or 5-fluorouracil. J Transl Med. 9:192011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hernlund E, Hjerpe E, Avall-Lundqvist E
and Shoshan M: Ovarian carcinoma cells with low levels of
beta-F1-ATPase are sensitive to combined platinum and
2-deoxy-D-glucose treatment. Mol Cancer Ther. 8:1916–1923. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Shin YK, Yoo BC, Chang HJ, Jeon E, Hong
SH, Jung MS, Lim SJ and Park JG: Down-regulation of mitochondrial
F1F0-ATP synthase in human colon cancer cells with induced
5-fluorouracil resistance. Cancer Res. 65:3162–3170.
2005.PubMed/NCBI
|
|
40
|
Hajra KM and Liu JR: Aoptosome dysfunction
in human cancer. Apoptosis. 9:691–704. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Loar P, Wahl H, Kshirsagar M, Gossner G,
Griffith K and Liu JR: Inhibition of glycolysis enhances
cisplatin-induced apoptosis in ovarian cancer cells. Am J Obstet
Gynecol. 202(371): e1–e8. 2010.PubMed/NCBI
|
